Ketamine and depression: The most important psychiatric discovery in half a century

Frank Menniti, Ph.D.
Adjunct Professor
School of Pharmacy
West Virginia University

Thursday, September 3rd 2015
12:00-1:00 p.m.
Alfond 304
UNE, Biddeford Campus

Lunch will be provided
Hosted by: Karen Houseknecht, Ph.D.
Sponsored by: The Center for Excellence in the Neurosciences and the COM Biomedical Sciences Department

Dr. Menniti is a founder of Mnemosyne Pharmaceuticals, Inc. and as Chief Scientific Officer is the architect of the Mnemosyne’s new therapeutic platform, the Subunit-selective NMDA Receptor Modulators. Prior to founding Mnemosyne, Dr. Menniti was a research scientist in the CNS Discovery group at Pfizer, Inc. in Groton CT (1992-2009). While at Pfizer Inc., Dr. Menniti was a principal in developing the scientific rationale for use of NMDA receptor NR2B antagonists for stroke, neuropathic pain, Parkinson’s disease, and depression and in the clinical development of the prototype NR2B antagonist CP-101,606. Dr. Menniti also was involved in developing the therapeutic utilities of phosphodiesterase inhibitors for neuropsychiatric disease. This includes the identification of PDE10A inhibitors for schizophrenia and Huntington’s disease, with the first PDE10A inhibitor to reach Phase II development. Dr. Menniti also led the discovery teams that advanced the first PDE9A inhibitor into Phase II testing for the treatment of Alzheimer’s disease and the first PDE5A inhibitor into Phase II testing to improve functional recovery after stroke. Dr. Menniti received his Ph.D. in Pharmacology from the University of North Carolina, Chapel Hill in 1987 and was a Staff Fellow in the laboratory of Dr. James W. Putney at the National Institute of Environmental Health Sciences from 1988-1992, participating in research elucidating the fundamentals of intracellular calcium signaling.